Breaking News

AbbVie, HotSpot Therapeutics Enter Strategic Immunology Alliance

Will leverage HotSpot's Smart Allostery drug discovery platform for the development of the first small molecule IRF5 for the treatment of autoimmune diseases.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie and HotSpot Therapeutics, Inc., a biotechnology company developing small molecule allosteric therapies for the treatment of cancer and autoimmune diseases, entered an exclusive worldwide collaboration and option to license agreement for HotSpot’s discovery-stage IRF5 program for the treatment of autoimmune diseases.   IRF5 is a transcription factor that acts as a key regulator of certain types of immune responses, and its dysregulation is strongly implicated in several poorly trea...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters